Ensuring the safe and effective FDA regulation of fecal microbiota transplantation

Journal of Law and the Biosciences

Volumn 2, Issue 3, 2016, Pages 396-415

  Sachs, Rachel E ^a   Edelstein, Carolyn A ^b  

^a HARVARD LAW SCHOOL   (United States)

^b OpenBiome   (United States)

Author keywords

Antibiotic resistance; FDA; Fecal transplantation; Microbiome

Indexed keywords

EID: 85055003694     PISSN: None     EISSN: 20539711     Source Type: Journal    
DOI: 10.1093/jlb/lsv032     Document Type: Article

References (59)

1. Shelley S.Magill et al., Multistate Point-Prevalence Survey of Health Care-Associated Infections, 370NEW ENG. J. MED. 1198, 1198 (2014)
2. Marya D. Zilberberg, Andrew F. Shorr & Marin H. Kollef, Increase in Adult Clostridium Difficile-Related Hospitalizations and Case-Fatality Rate, United States, 2000-2005, 14 EMERG. INFECT. DIS. 929, 929 (2008)
3. The White House, National Action Plan for Combating Antibiotic-Resistant Bacteria, 60, Mar. 2015, https://www.whitehouse.gov/sites/default/files/docs/national action plan for combating antiboticresistant bacteria.pdf (accessed June 18, 2015)
4. Erik R. Dubberke & Margaret A. Olsen, Burden of Clostridium Difficile on the Healthcare System, 55 CLIN. INFECT. DIS. S88, S88 (2012)
5. Ciaran P. Kelly & J.Thomas LaMont, Clostridium Difficile-More Difficult Than Ever, 359 NEW ENG. J. MED. 1932, 1936 (2008)
6. Laurica A. Petrella et al., Decreased Cure and Increased Recurrence Rates forClostridiumDifficile InfectionCaused by the Epidemic C. Difficile BI Strain, 55CLIN. INFECT. DIS. 351, 352 (2012)
7. Gauree G. Konijeti et al., Cost-Effectiveness of Competing Strategies for Management of Recurrent Clostridium Difficile Infection: A Decision Analysis, 58CLIN. INFECT. DIS. 1507, 1507 (2014)
8. J. C. O'Horo et al., Treatment of Recurrent Clostridium Difficile Infection: A Systematic Review, 42 INFECTION 43, 43 (2014)
9. Zain Kassam, Christine H. Lee & Richard H. Hunt, Review of the Emerging Treatment of Clostridium difficile Infection with Fecal Miocrobiota Transplantation and Insights into Future Challenges, 34 CLIN. LAB. MED. 787 (2014)
10. Food & Drug Administration, Fecal Microbiota for Transplantation: Scientific and Regulatory Issues 309, May 2, 2013, http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetings Conferences/UCM352903.pdf (accessed June 18, 2015)
11. Matthew J. Hamilton et al., Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection, 107 AM. J. GASTROENTEROL 761, supplementary appendix 1 (2012)
12. BenEiseman et al., FecalEnema as an Adjunct in the Treatment of PseudomembranousEnterocolitis, 44 SURGERY 854 (1958)
13. Zain Kassam et al., FecalMicrobiota for Clostridium difficile Infection: Systematic Review andMeta-Analysis, 108 AM. J. GASTROENTEROL 500, 508 (2013)
14. Sumei Sha et al., Systematic Review: FaecalMicrobiota Transplantation Therapy for Digestive and Nondigestive Disorders in Adults and Children, 39 ALIMENT. PHARMACOL. THER. 1003, 1004 (2014)
15. Els van Nood et al., Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile, 368 NEW ENG. J. MED. 407, 409 (2013)
16. Lawrence J. Brandt, et al., Long-Term Follow-up of Colonoscopic Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection, 107 AM. J.GASTROENTEROL. 1079, 1079 (2012)
17. Matthew J. Hamilton et al., High-Throughput DNA Sequence Analysis Reveals Stable Engraftment of Gut Microbiota Following Transplantation of Previously Frozen Fecal Bacteria, 4 GUTMICROBES 125 (2013)
18. CharlieG. Buffie et al., PrecisionMicrobiome Reconstitution Restores Bile AcidMediated Resistance to Clostridium difficile, 517 NATURE 205 (2015)
19. Seres Therapeutics, Seres Health Presents Final Data for Study of SER-109 in Recurrent Clostridium difficile Infection at ICAAC 2014 Conference, Sept. 10, 2014, http://serestherapeutics.com/ news/newsroom/seres health presents final data for study of ser-109 in recurrent clostridium difficile infection at icaac 2014 conference/ (accessed June 18, 2015)
20. Sammy Caiola, Sacramento Nonprofit Center's Collection Helps Patients with Intestinal Disease, SACRAMENTO BEE, Mar. 13, 2015, http://www.sacbee.com/news/local/health-and-medicine/healthy-choices/article14072969.html (accessed June 18, 2015)
21. OpenBiome, OpenBiome Receives Grant to Support FMT Patient Safety Study, Aug. 7, 2014, http://www. openbiome.org/press-releases/2014/8/8/openbiome-receives-grant-to-support-fmt-patient-safety-study (accessed June 18, 2015)
22. Paul Moayyedi et al., Canadian Association of Gastroenterology Position Statement: Fecal Microbiota TransplantTherapy, 28, CAN. J. GASTROENTEROL. HEPATOL. 66, 67 (2014)
23. Alex Lash, With Vedanta Deal, J & J Marks Big-Pharma Milestone in the Microbiome, XCONOMY, Jan. 13, 2015, http://www.xconomy.com/boston/2015/01/13/with-vedanta-deal-jj-marks-big-pharma-milestonein-the-microbiome/ (accessed June 18, 2015)
24. Food & Drug Administration, Public Workshop: Fecal Microbiota for Transplantation, Announcement of May 2013 Workshop, http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetings Conferences/ucm341643.htm (accessed June 18, 2015)
25. Mark B. Smith, Colleen Kelly & Eric J.Alm, How to Regulate Faecal Transplants, 506NATURE 290, 290 (2014)
26. J. Gregory Caporaso et al., Moving Pictures of the Human Microbiome, 12GENOME BIOL. R50 (2011)
27. Lawrence A. David et al., Host Lifestyle Affects Human Microbiota on Daily Timescales, 15 GENOME BIOL. R89 (2014)
28. Joseph A. Levitt&John V. Kelsey, The Orphan Drug Regulations and Related Issues, 48 FOOD & DRUG L.J. 525, 526-28 (1993)
29. Yaniv Heled, Patents vs. Statutory Exclusivities in Biological Pharmaceuticals-Do We Really Need Both?, 18MICH. TELECOMM. & TECH. L. REV. 419, 423 n.5 (2012)
30. Rebecca S. Eisenberg, The Shifting Functional Balance of Patents and Drug Regulation, 19 HEALTH AFF. 119, 122 (2001)
31. Arti K. Rai, The Information Revolution Reaches Pharmaceuticals: Balancing Innovation Incentives, Cost, and Access in the Post-Genomics Era, 2001 U. ILL. L. REV. 173, 183 (2001)
32. Richard A. Merrill, The Architecture of Government Regulation of Medical Products, 82 VA. L. REV. 1753, 1790-91 (1996)
33. Aaron S. Kesselheim & DanielH. Solomon, Incentives for Drug Development-The Curious Case of Colchicine, 362 NEW ENG. J. MED. 2045, 2045 (2010)
34. Yesha Patel & Martha M. Rumore, Hydroxyprogesterone Caproate Injection (Makena) One Year Later, 37 P&T 405, 406 (2012)
35. Food & Drug Administration, Questions and Answers on Updated FDA Statement on Compounded Versions of Hydroxyprogesterone Caproate, 2012, http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm310215.htm (accessed June 18, 2015)
36. Food & Drug Administration, Orphan Drug Designation for Fecal Microbiota, Mar. 10, 2014, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD Results 2.cfm?Index Number=421013 (accessed June 18, 2015)
37. Rebiotix, Rebiotix Announces First Ever Randomized Study of a Microbiota-Based Drug for Recurrent Clostridium difficile Infection Under an FDA IND, Dec. 16, 2014, http://www.rebiotix.com/index.php/ first-randomized-clinical-trial-microbiota-drug-clostridium-difficile-infection (accessed June 18, 2015)
38. Alex Park, Should We Regulate Poop as a Drug?, MOTHER JONES, Aug. 18, 2014, http://www.motherjones.com/environment/2014/ 08/fecal-transplant-fda-openbiome-rebiotix (accessed June 18, 2015)
39. Food & Drug Administration, Unapproved Drugs Initiative, 2014, http://www.fda.gov/Drugs/Guidance-ComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionson-UnapprovedDrugs/ucm118990.htm (accessed June 18, 2015)
40. Kurt R. Karst, KV Lawsuit Involving Makena and Compounded 17P Concludes in Sopranos Style, FDA LAW BLOG, July 7, 2014, http://www.fdalawblog.net/fda law blog hyman phelps/2014/07/ kv-lawsuit-involving-makena-and-compounded-17p-concludes-in-sopranos-style.html (accessed June 18, 2015)
41. http://prescriptions.blogs.nytimes.com/2011/05/31/ the-hidden-price-of-drugs/ (accessed June 18, 2015)
42. http://www.youtube.com/watch?v=xLIndT7fuGo (accessed June 18, 2015)
43. http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/ QuestionsaboutTissues/ucm102842.htm (accessed June 18, 2015)
44. Anne Vrieze et al., Transfer of IntestinalMicrobiota From LeanDonors Increases Insulin Sensitivity in Individuals WithMetabolic Syndrome, 143 GASTROENTEROLOGY 913, 913 (2012)
45. Stephen M. Collins et al., The Adoptive Transfer of Behavioral Phenotype Via the Intestinal Microbiota: Experimental Evidence and Clinical Implications, 16CURR. OP. MICROBIOL. 240, 240 (2013)
46. Food & Drug Administration, Keeping Blood Transfusions Safe: FDA's Multi-Layered Protections for Donated Blood, 2013, http://www.fda.gov/BiologicsBloodVaccines/ SafetyAvailability/BloodSafety/ucm095522.htm (accessed June 18, 2015)
47. Food & DrugAdministration, Keeping Blood Transfusions Safe: FDA'sMulti-Layered Protections for Donated Blood 2013, http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ BloodSafety/ucm095522.htm (accessed June 18, 2015)
48. Eliane Gluckman et al., Hematopoietic Reconstitution in a Patient with Fanconi's Anemia by Means of Umbilical-Cord Blood from an HLA-Identical Sibling, 321 NEW ENG. J. MED. 1174, 1174 (1989)
49. Jennifer Kulynych, Blood As A Biological 'Drug': Scientific, Legal, and Policy Issues in the Regulation of Placental and Umbilical Cord Stem Cell Transplantation, 32U. RICH. L. REV. 407, 408 (1998)
50. Richard A. Merrill, Human Tissues and Reproductive Cloning: New Technologies Challenge FDA, 3 HOUS. J. HEALTH L. & POL'Y 1, 10 (2002)
51. Food & Drug Administration, Tissue Reference Group: FY 2012 Update, 2012, http://www.fda.gov/ biologicsbloodvaccines/tissuetissueproducts/regulationoftissues/ucm152857.htm (accessed June 18, 2015)
52. http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ UCM352902.pdf (accessed June 18, 2015)
53. http://www.gastro.org/ research/Joint Society FMT?Guidance.pdf (accessed June 18, 2015)
54. David C. Radley et al., Off-label Prescribing Among Office-Based Physicians, 166 ARCH. INTERN. MED. 1021, 1021 (2006)
55. Amy Kapczynski & Talha Syed, The Continuum of Excludability and the Limits of Patents, 122 YALE L. J. 1900 (2013)
56. Seres Therapeutics, About Seres Therapeutics, 2015, http://serestherapeutics.com/about/about seres therapeutics/ (accessed June 18, 2015)
57. Food & Drug Administration, Tissue Reference Group: FY 2012 Update, 2012, http://www.fda.gov/ biologicsbloodvaccines/tissuetissueproducts/regulationoftissues/ucm152857.htm (accessed June 18, 2015)
58. Food & Drug Administration, Drug Shortage Management, 12, 2014, http://www.fda.gov/downloads/ AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/ UCM079936.pdf (accessed June 18, 2015)
59. Jody Freeman & David B. Spence, Old Statutes, New Problems, 163 U. PA. L. REV. 1 (2014)